Drug Type TCR therapy |
Synonyms NY-ESO-1-transduced T-cells - Guangzhou-Pharmaceutical, TAEST 16001, TAEST-16001 + [1] |
Target |
Mechanism NY-ESO-1 inhibitors(Cancer/testis antigen 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Soft Tissue Sarcoma | Phase 2 | CN | 08 Jul 2022 | |
Soft Tissue Sarcoma | Phase 2 | CN | 08 Jul 2022 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 23 Mar 2020 | |
Osteosarcoma | Phase 1 | CN | 10 Jun 2018 | |
Neoplasms | Preclinical | US | - | |
Neoplasms | Preclinical | US | - |
Phase 2 | Soft Tissue Sarcoma NY-ESO-1 | HLA-A*02:01 | 8 | Cyclophosphamide and fludarabine | pdccrxdusd(iotuupsfqr) = n=7 qpszcbgmyj (bsfdcxtzuo ) View more | Positive | 24 May 2024 | |
NCT04318964 (Pubmed) Manual | Phase 1 | 12 | ytngdmgxpr(zdlgegrpfa) = chukvxrwva wuftkepjcp (eecqnvdkpj ) View more | Positive | 15 Aug 2023 | ||
NCT04318964 (ASCO2022) Manual | Phase 1 | 12 | cyclophosphamide+fludarabine+NY-ESO-1–specific TCR T-cells (TAEST16001) | ltklnwwayo(itbxuktcdu) = llgbmiuzye xlvnjoauqc (ydcfihdjvw ) View more | Positive | 02 Jun 2022 |